LOW DOSAGE
STANOZOLOLUM TREATMENT IN CHILDREN WITH PARTIAL GROWTH HORMONE DEFICIENCY
Chen HS, Du ML, Ma HM, Li YH
Department of Pediatrics, The
First Affiliated Hospital, Sun Yat-sen University of Medical Sciences,
China
Objective: to analyze the efficacy
of stanozololum on the growth of the children with partial growth hormone
deficiency (PGHD).
Methods: Fourteen prepubertal
children with PGHD, 9 boys and 5 girls, aged from 3-12 years, were given
low dosage stanozololum (20-40ug/kg) treatment. After 6.54��2.56 (4-9)months treatment
period, the efficacy of the treatment was evaluated according to growth
velocity (GV), height z score for chronological age (HtSDSca), height z
score for bone age (HtSDSba),
the ratio of the increased height age/ the increased bone age(��HA/��BA), predicted adult height and
IGF-I.
Results: The GV of the patients
increased from ��4.18��1.25 �� cm/a to ��8.72��2.54�� cm/a ��p=0��. HtSDSca increased from (-2.58��0.55) to (-2.36��0.6) ��p=0.001��; HtSDSba increased from (-1.17��0.58) to (-0.91��0.65) ��p<0.05��. Mean ��HA/��BA was ��1.91��1.67��; of the 14 children , the ��HA/��BA<1 in 4 individuals and
>1 in the other 10. Predicted adult height increases from ��156.2��4.76�� cm to ��158.08 ��6.59�� cm ��p<0.05��. IGF-I level increased from ��286.54��142.21�� ng/ml to (534��198.95) ng/ml (p<0.01). Z
score of IGF-I increased from ��-0.48��0.74�� to ��0.87��0.82�� (p<0.01).
Conclusion:
Short-term treatment of low dosage stanozololum facilitates the growth of
prepubertal children with PGHD. We presume that it affects the growth by
increasing the IGF-I secretion of the patients. It is necessary to observe
the bone age carefully because the acceleration in bone maturation is more
than the height gain in some individuals.